Datopotamab deruxtecan (Datroway)
New indication (Breast Neoplasms). The wording is on the EMA page.
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
New indication (Breast Neoplasms). The wording is on the EMA page.
Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease